Transfusion Medicine最新文献_第9页

Plenary session I 全体会议 I

IF 1.5 4区医学

Transfusion Medicine Pub Date : 2024-09-13 DOI: 10.1111/tme.13078

引用次数: 0

Wednesday 18 September 2024 Simultaneous sessions 2024 年 9 月 18 日星期三同时举行的会议

IF 1.5 4区医学

Transfusion Medicine Pub Date : 2024-09-13 DOI: 10.1111/tme.13085

引用次数: 0

Plenary session III 全体会议 III

IF 1.5 4区医学

Transfusion Medicine Pub Date : 2024-09-13 DOI: 10.1111/tme.13083

引用次数: 0

Thursday 19 September 2024 Simultaneous Sessions 2024 年 9 月 19 日星期四同时举行的会议

IF 1.5 4区医学

Transfusion Medicine Pub Date : 2024-09-13 DOI: 10.1111/tme.13088

引用次数: 0

Plenary session II 第二次全体会议

IF 1.5 4区医学

Transfusion Medicine Pub Date : 2024-09-13 DOI: 10.1111/tme.13082

引用次数: 0

Risk factors for red blood cell alloimmunization in patients with hematologic malignancy 血液系统恶性肿瘤患者发生红细胞同种免疫的风险因素

IF 1.5 4区医学

Transfusion Medicine Pub Date : 2024-09-12 DOI: 10.1111/tme.13096

Pakthipa Pattarakosol, Nattarat Lorucharoen, Phandee Watanaboonyongcharoen, Ponlapat Rojnuckarin

{"title":"Risk factors for red blood cell alloimmunization in patients with hematologic malignancy","authors":"Pakthipa Pattarakosol, Nattarat Lorucharoen, Phandee Watanaboonyongcharoen, Ponlapat Rojnuckarin","doi":"10.1111/tme.13096","DOIUrl":"https://doi.org/10.1111/tme.13096","url":null,"abstract":"IntroductionPatients with hematologic malignancy have a higher risk of developing red blood cell (RBC) alloimmunization which can delay blood transfusion. Information on the risk factors for alloimmunization in this group is still limited. This study aimed to determine the prevalence and predictors of RBC alloimmunization among these patients.Materials and MethodsElectronic medical records of the patients with acute myeloid leukaemia (AML), acute lymphoid leukaemia (ALL), multiple myeloma (MM) and lymphoma from a tertiary care hospital between January 2018 and December 2022 were retrospectively reviewed. Clinical, demographic and transfusion history data of the included patients were analysed.ResultsOf the 983 patients with hematologic malignancy, 798 were included in the study. The prevalence of RBC alloantibodies in this population was 4.8% (38 patients). The alloimmunization rate of each subgroup was as followed: AML 9.1%, ALL 2.9%, MM 3.8% and lymphoma 2.5%. The most common alloantibodies were anti‐Mia, anti‐E and anti‐Lea. The majority (29/38, 76.3%) of alloimmunization had a single alloantibody. RBC autoantibody was detected in 10 patients. The detection of autoantibodies and having AML were independently associated with RBC alloimmunization (adjusted odds ratio [aOR] 13.41, 95% confidence interval [CI] 2.00–89.72, p = 0.007 and aOR 11.44, 95% CI 2.02–64.72, p = 0.006, respectively).ConclusionThe prevalence of RBC alloimmunization in the patients with hematologic malignancy was 4.8%. The alloimmunization rate of the AML subgroup was higher than those of other hematologic malignancies. The detection of autoantibodies and the AML diagnosis were identified as potential risk factors for RBC alloimmunization.","PeriodicalId":23306,"journal":{"name":"Transfusion Medicine","volume":"27 1","pages":""},"PeriodicalIF":1.5,"publicationDate":"2024-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142217242","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Implementation challenges of electronic blood transfusion safety systems: Lessons from an international, multi‐site comparative case study 输血安全电子系统的实施挑战：国际多站点比较案例研究的经验教训

IF 1.5 4区医学

Transfusion Medicine Pub Date : 2024-09-10 DOI: 10.1111/tme.13095

Stijn Horck, Nick Fahy, Trisha Greenhalgh

{"title":"Implementation challenges of electronic blood transfusion safety systems: Lessons from an international, multi‐site comparative case study","authors":"Stijn Horck, Nick Fahy, Trisha Greenhalgh","doi":"10.1111/tme.13095","DOIUrl":"https://doi.org/10.1111/tme.13095","url":null,"abstract":"BackgroundSevere transfusion reactions resulting from errors in matching the correct blood with the correct patient are considered never events. Despite the relative technical simplicity of barcode scanning for patient‐blood bag matching, the adoption and universal application of this safety measure are by no means universal. This study highlights the logistical and institutional challenges associated with spreading, scaling up, and sustaining such IT‐supported safety measures in healthcare.Study Design and MethodsWe report findings from a 5‐year, prospective, multi‐site case study conducted across one hospital in England and three hospitals in the Netherlands. Ethnographic methods, including interviews and observations, were used at each site to investigate the implementation of barcode scanning‐supported safety pathways for blood transfusions.ResultsSignificant variation was observed across the sites in the adoption and implementation of barcode scanning‐supported safety pathways. Despite the potential for reducing transfusion errors, the introduction of this innovation was met with varying levels of success in different settings.DiscussionThis study highlights the critical role of inter‐hospital learning and flexible system design in successfully implementing barcode scanning‐supported safety pathways for blood transfusions. A more structured, national‐level network for knowledge sharing could enhance the spread and sustainability of such innovations across healthcare settings.","PeriodicalId":23306,"journal":{"name":"Transfusion Medicine","volume":"05 1","pages":""},"PeriodicalIF":1.5,"publicationDate":"2024-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142217244","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Characterising practice patterns of human derived, lyophilized coagulation concentrates within the trauma quality improvement program registry 在创伤质量改进计划登记册中描述人源冻干凝血浓缩物的实践模式

IF 1.5 4区医学

Transfusion Medicine Pub Date : 2024-09-10 DOI: 10.1111/tme.13094

Chester A. Rosenthal, David J. Douin, Mitch J. Cohen, Julie A. Rizzo, Michael D. April, Steven G. Schauer

{"title":"Characterising practice patterns of human derived, lyophilized coagulation concentrates within the trauma quality improvement program registry","authors":"Chester A. Rosenthal, David J. Douin, Mitch J. Cohen, Julie A. Rizzo, Michael D. April, Steven G. Schauer","doi":"10.1111/tme.13094","DOIUrl":"https://doi.org/10.1111/tme.13094","url":null,"abstract":"ObjectivesWe seek to describe the current practice pattern use of prothrombin complex concentrate (PCC) and fibrinogen concentrate (FC) in trauma patients.BackgroundTrauma‐induced coagulopathy (TIC) and endotheliopathy of trauma (EOT) contribute significantly to mortality from traumatic haemorrhage. FC, and 4‐factor PCC are potential treatments for EOT and TIC, respectively.Materials and MethodsWe obtained data from the Trauma Quality Improvement Program (TQIP) registry and identified patients who received either PCC or FC using procedural codes. We used descriptive statistics to characterise practice patterns of these products.ResultsThere were 6 714 002 total encounters within the TQIP from 2017 to 2022, of which 10 589 received PCC and 3009 received FC. Of the recipients, there were 35 that received both products. There were 44 that received both. The median age of PCC recipients was 77 (69–84) with 19 patients <15 years of age with the youngest being 2 years of age. There was a general upward trend in the number of facilities with documented use of PCC: 155/744, 168/766, 189/764, 206/780, 234/795, and 235/816, respectively. The median age of FC recipients was 57 (32–75) with 48 patients <15 years of age with the youngest being 1 year of age. There was a minor downward trend in the number of facilities that had documented use of FC: 55, 44, 39, 32, 38 and 40.ConclusionsThe administration of PCC and FC remains uncommon, although there appears to be an upward trend of PCC use. Most PCC use appeared to be for anticoagulation reversal in the setting of head trauma. Data guiding the use of these products are necessary as these products become more recognised as adjuncts to traumatic haemorrhage control.","PeriodicalId":23306,"journal":{"name":"Transfusion Medicine","volume":"13 1","pages":""},"PeriodicalIF":1.5,"publicationDate":"2024-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142217106","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

XLI Annual Scientific Meeting of the British Blood Transfusion Society 17-19 September 2024, SEC, Glasgow, Scotland. 英国输血协会第四十一届科学年会，2024 年 9 月 17-19 日，苏格兰格拉斯哥 SEC。

IF 1.5 4区医学

Transfusion Medicine Pub Date : 2024-09-01 DOI: 10.1111/tme.13089

引用次数: 0

Evaluation of platelet concentrates prepared using different methods after overnight holding (18-24 h) of whole blood at room temperature. 对室温下全血过夜（18-24 小时）后用不同方法制备的血小板浓缩物进行评估。

IF 1.5 4区医学

Transfusion Medicine Pub Date : 2024-08-01 Epub Date: 2024-06-30 DOI: 10.1111/tme.13064

Deviprasanna Mohanty, Rahul Chaurasia, Anand Kumar, Gopal Kumar Patidar, Hem Chandra Pandey, Arulselvi Subramanian

{"title":"Evaluation of platelet concentrates prepared using different methods after overnight holding (18-24 h) of whole blood at room temperature.","authors":"Deviprasanna Mohanty, Rahul Chaurasia, Anand Kumar, Gopal Kumar Patidar, Hem Chandra Pandey, Arulselvi Subramanian","doi":"10.1111/tme.13064","DOIUrl":"10.1111/tme.13064","url":null,"abstract":"Background and objectives: Regulatory requirement of fixed holding time (6 h) of whole blood (WB) at room temperature, that is, 22-24°C (RT) results in sub-optimal component separation. The aim was to evaluate the platelet concentrates (PC) prepared by both platelet rich plasma (PRP) and buffy coat (BC) methods after overnight hold (18-24 h) at RT.Materials and methods: A prospective experimental study was performed. A total of 48 WB units collected were divided into four groups (12 each) control-1 (C1) and test-1 (T1) for PRP and control-2 (C2) and test-2 (T2) for the BC method. Control groups were processed within 6 h, and in test groups, components were prepared after overnight hold, followed by evaluation of quality parameters.Results: Irrespective of the method used, all PCs had similar volume, platelet yield, swirling, no bacterial contamination, RBC contamination, PaO2 and PaCO2 levels. PCs in the T1 group had significant differences in glucose and MPV values on d1, which were resolved by d5 of storage. PCs in T2 has significant differences in pH, glucose, and MPV levels throughout storage. PRBC in test and control groups had similar quality parameters till d42 of storage. FFPs in all tests were noninferior to the concurrent control groups till 3 months of storage.Conclusion: Overnight holding of WB had no lasting deleterious changes. Though a few biochemical parameters in the test groups were significantly different, they can be accepted to improve the logistics of component separation. Overall PRP method seemed to have a better result than the BC method after an overnight hold.","PeriodicalId":23306,"journal":{"name":"Transfusion Medicine","volume":" ","pages":"311-318"},"PeriodicalIF":1.5,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141470918","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0